Neurocrine Biosciences NBIX
NASDAQ NBIX
$174.41 +5.27 (+3.12%)
At close: Nov 11, 2026 · 4:00 PM EST

Neurocrine Biosciences (NBIX) Cash from Operations (2009 - 2026)

Updated

Neurocrine Biosciences (NBIX) posted Cash from Operations of $395.2 million for Q3 2026, up 73.7% from $227.5 million a year earlier and up 189.7% from the prior quarter.

Analysis

Neurocrine Biosciences (NBIX) Cash from Operations (2009 - 2026) Analysis & Trends

For the trailing twelve months through Sep 30, 2026, Cash from Operations at Neurocrine Biosciences was $1.07 billion, up 67.4% year-over-year; for FY2025, it came in at $782.7 million, up 31.5% from FY2024.

  • Annual Cash from Operations has increased for seven consecutive years, with a five-year compound annual growth rate of 27.9% (FY2020 to FY2025).
  • In prior years, Neurocrine Biosciences' Cash from Operations was $595.4 million in FY2024 (+52.7%), $389.9 million in FY2023 (+14.9%), $339.4 million in FY2022 (+32.3%) and $256.5 million in FY2021 (+12.3%).
  • The Q3 2026 figure stands as the highest quarterly Cash from Operations in data going back to Q3 2010.
  • On a year-over-year basis, Cash from Operations has increased in each of the last six quarters, with growth averaging 55.1% over the last eight quarters.
  • The strongest year-over-year quarter for Cash from Operations in the past five years was Q1 2026, with growth of 125.0%; the weakest was Q4 2021, with a decline of 95.6%.
  • According to Business Quant data, Cash from Operations for the three prior quarters was $136.4 million (Q2 2026), $145.8 million (Q1 2026) and $388.4 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 11.40 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 7.72 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 7.61 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 6.56 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 4.67 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 4.24 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 5.04 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 5.38 Bn
10 Neurocrine Biosciences 17.13 Bn 13.21 Bn 1.10 Bn 395.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 395.20 Mn
Jun 30, 2026 136.40 Mn
Mar 31, 2026 145.80 Mn
Dec 31, 2025 388.40 Mn
Sep 30, 2025 227.50 Mn
Jun 30, 2025 102.00 Mn
Mar 31, 2025 64.80 Mn
Dec 31, 2024 242.50 Mn
Sep 30, 2024 158.00 Mn
Jun 30, 2024 64.60 Mn
Mar 31, 2024 130.30 Mn
Dec 31, 2023 123.50 Mn
Sep 30, 2023 212.00 Mn
Jun 30, 2023 179.60 Mn
Mar 31, 2023 -125.20 Mn
Dec 31, 2022 143.00 Mn
Sep 30, 2022 98.80 Mn
Jun 30, 2022 138.10 Mn
Mar 31, 2022 -40.50 Mn
Dec 31, 2021 4.20 Mn
API Access

Neurocrine Biosciences Cash from Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-operations&ticker=NBIX&period=max&api_key=YOUR_API_KEY